Pharmaceutical News

RSS

Breast cancer patients more likely to have joint pain from taking AIs: Study

Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.

10 Nov 2010

Lower-protein infant formula helps attain same growth rate as breastfed infants

Newly published findings indicate that infants fed a lower protein infant formula developed by Pfizer Nutrition gained weight at a similar rate to those who were breastfed, according to a study published online today in the European Journal of Clinical Nutrition. Pfizer Nutrition has always recognized that breast milk is the best source of infant nutrition. The study established that infants fed a new, lower-protein infant formula attained the same growth rate and growth pattern as breastfed infants.

10 Nov 2010

Using mild painkillers during pregnancy can increase risk of male reproductive disorders

New evidence has emerged that the use of mild painkillers such as paracetamol, aspirin and ibuprofen, may be part of the reason for the increase in male reproductive disorders in recent decades.

10 Nov 2010

Malaria drug artesunate found more effective than quinine at preventing severe falciparum malaria deaths in children, study says

Researchers found that the death rate among children diagnosed with severe falciparum malaria was almost one-fourth lower when they received the drug artesunate rather than the standard treatment of quinine, according to research which was presented at the American Society for Tropical Medicine and Hygiene (ASTMH) over the weekend and published Monday in the Lancet, HealthDay News/U.S. News and World Report writes.

10 Nov 2010

Clot-busting drug remains the most beneficial emergency treatment for strokes

The clot-busting drug rt-PA remains the most beneficial proven emergency treatment for strokes caused by blood clots, according to an editorial in the November issue of Archives of Neurology by Dr. Jos- Biller.

10 Nov 2010

Flu vaccination programs can protect employee health, save businesses money

Each year, influenza poses a tremendous burden on working adults and the many businesses that employ them, contributing to absenteeism and lost productivity. Yet, annual influenza immunization rates remain very low. New data out today show that employer-sponsored influenza vaccination programs held early in the flu season not only protect employee health, but save businesses money.

10 Nov 2010

Restylane boosts people's first impression

A recent study demonstrating that the treatment of nasolabial folds with Restylane positively influences the first impression that an individual projects was published by Dr. Steven Dayan (www.drdayan.com) and DeNova research in the November 2010 issue of Dermatologic Surgery, a leading Dermatology journal. In a study 20 patients received Restylane the popular hyaluronic filler to fill in the nasolabial folds which run from the side of the nose to the side of the mouth.

10 Nov 2010

Aromatase inhibitors increase side effects in women undergoing breast cancer therapy

Women being treated for breast cancer with aromatase inhibitors may experience extremely low estrogen levels resulting in a wide variety of side effects that a typical postmenopausal woman without cancer may not experience.

10 Nov 2010

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals), a specialty central nervous system (CNS) pharmaceutical company, announced results of a new analysis of a Phase 2a study, which previously demonstrated reduced pain, fatigue and tenderness in patients with Fibromyalgia Syndrome (FMS) following bedtime administration of very low dosage (VLD) cyclobenzaprine (CBP).

10 Nov 2010

Orexo third quarter net revenues decrease to MSEK 35.9

"During the third quarter, Abstral™ sales were 480% higher than in the same period last year. Sales of Edluar™, Orexo's sublingual zolpidem treatment for insomnia, continue to grow more strongly from a low base, with new stock being ordered for the first time since launch and generating royalty income for Orexo.

10 Nov 2010

Health reform policy: Flexible spending, device taxes and waivers

One health law provision will be a bummer for people who use the tax-free dollars stored in flexible spending accounts, Kaiser Health News reports. "Starting in January, you'll no longer be able to use your FSA for over-the-counter drugs and medicines unless you have a doctor's prescription. Experts agree that the new rules will likely discourage people from tapping their FSAs for routine purchases of aspirin, vitamins, cough medicine and other drugstore essentials" (Andrews, 11/8).

10 Nov 2010

Federal appellate court rules in favor of Merck in TEMODAR patent infringement suit

Merck & Co., Inc. said today that a federal appellate court ruled in its favor in a TEMODAR patent infringement suit against Barr Laboratories, an affiliate of Teva Pharmaceuticals.

10 Nov 2010

Baxa launches ExactaMix 1200 Automated Compounding Device

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today introduced the ExactaMix 1200 Automated Compounding Device (ACD) for small- to mid-sized hospital pharmacies in need of an automated approach to compounding large-volume parenteral doses.

9 Nov 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).

9 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.

9 Nov 2010

Ultrasound needle guidance improves performance and outcomes of knee injections

The use of ultrasound needle guidance improves the performance, outcomes and the cost-effectiveness of knee injections in people with osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Fake antimalarial medications uncovered across Ghana

Substandard and counterfeit versions of thirteen key antimalarial medicines were uncovered in multiple locations across Ghana by the Medicines Quality Monitoring surveillance program. Set up by the Ghana Food and Drugs Board (FDB) in collaboration with the U.S. Pharmacopeial Convention (USP) and the U.S. Agency for International Development (USAID), the program samples antimalarials across the public and private sectors.

9 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Pharmaceutical News

Breast cancer patients more likely to have joint pain from taking AIs: Study

Lower-protein infant formula helps attain same growth rate as breastfed infants

Using mild painkillers during pregnancy can increase risk of male reproductive disorders

Malaria drug artesunate found more effective than quinine at preventing severe falciparum malaria deaths in children, study says

Clot-busting drug remains the most beneficial emergency treatment for strokes

Flu vaccination programs can protect employee health, save businesses money

Restylane boosts people's first impression

Aromatase inhibitors increase side effects in women undergoing breast cancer therapy

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

Orexo third quarter net revenues decrease to MSEK 35.9

Health reform policy: Flexible spending, device taxes and waivers

Federal appellate court rules in favor of Merck in TEMODAR patent infringement suit

Baxa launches ExactaMix 1200 Automated Compounding Device

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Research report on current and evolving technologies in drug delivery

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

Ultrasound needle guidance improves performance and outcomes of knee injections

Fake antimalarial medications uncovered across Ghana

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News